524. Hepatic Safety of Remdesivir Across Phase 3 Placebo-controlled COVID-19 Studies

BACKGROUND: Remdesivir (RDV), an RNA polymerase inhibitor approved to treat COVID-19, is extensively metabolized by the liver. Because COVID-19 can impact hepatic function and Phase 1 RDV trials showed transient Grade 1-2 transaminase elevations, subsequent studies have aimed to assess the hepatic s...

Descripción completa

Detalles Bibliográficos
Autores principales: Force, Lindsey, Blair, Chris, Duckworth, Joshua, Abdelghany, Mazin, Nguyen, Ngoc-Quyen, Hyland, Robert H, Davies, Santosh, Chen, Shuguang, Zhao, Yang, Fu, Olivia
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2023
Materias:
Abstract
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10677836/
http://dx.doi.org/10.1093/ofid/ofad500.593

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10677836/
http://dx.doi.org/10.1093/ofid/ofad500.593

Ejemplares similares